Dabigatran etexilate and COVID-19
| Main Author: | Domina Petric |
|---|---|
| Format: | info publication-preprint Journal |
| Terbitan: |
, 2021
|
| Online Access: |
https://zenodo.org/record/4697604 |
Daftar Isi:
- Thrombotic complications are frequent in COVID-19. There is evidence supporting the use of prophylactic dose low molecular weight heparin (LMWH) as prophylaxis for venous thromboembolism in critically ill patients. Indeed, all patients with COVID-19 that are admitted to hospital should receive prophylactic dose of LMWH. Dabigatran etexilate (Pradaxa) is an active direct thrombin inhibitor that inhibits clot-bound and circulating thrombin. Based on virtual screening results dabigatran etexilate is also a potential SARS-CoV-2 inhibitor. Therefore, dabigatran could be a new therapeutic option for the prophylaxis and treatment of COVID-19 associated thromboembolism, but further clinical research is mandatory.